Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies.

We determined the contribution of cytochrome P450 (CYP) isoforms to the metabolism of midazolam by kinetic analysis of human liver microsomes and CYP isoforms and by examining the effect of chemical inhibitors and monoclonal antibodies against CYP isoforms in vitro. Midazolam was metabolized to 1'-hydroxymidazolam (1'-OH MDZ) by human liver microsomes with a Michaelis-Menten constant (Km) of 4.1 (1.0) (mean (SD)) micromol litre(-1) and a maximum rate of metabolism (Vmax) of 5.5 (1.1) nmol min(-1) mg protein(-1) (n = 6). Of the nine representative human liver CYP isoforms, CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, 3A4 and 3A5, three (CYP2B6, 3A4 and 3A5) showed midazolam 1'-hydroxylation activity, with Kms of 40.7, 1.7 and 3.0 micromol litre(-1), respectively, and Vmax values of 12.0, 3.3 and 13.2 nmol min(-1) nmol P450(-1), respectively (n = 4). Midazolam 1'-hydroxylation activity of human liver microsomes correlated significantly with testosterone 6beta-hydroxylation activity, a marker of CYP3A activity (r2 = 0.77, P = 0.0001), but not with S-mephenytoin N-demethylation activity, a marker of CYP2B6 activity (r2 < 0.01, P = 0.84) (n = 11). Troleandomycin and orphenadrine, chemical inhibitors of CYP isoforms, inhibited the formation of 1'-OH MDZ by human liver microsomes. Monoclonal antibody against CYP3A4 inhibited the formation of 1'-OH MDZ by 79%, whereas monoclonal antibody against CYP2B6 had no effect on midazolam 1'-hydroxylation by human liver microsomes (n = 5). These results indicate that only CYP3A4, but not CYP2B6 or CYP2C, is involved in the metabolism of midazolam in vitro.

[1]  S. Imaoka,et al.  Metabolism of a New Local Anesthetic, Ropivacaine, by Human Hepatic Cytochrome P450 , 1995, Anesthesiology.

[2]  A. Breckenridge,et al.  CIMETIDINE: INTERACTION WITH ORAL ANTICOAGULANTS IN MAN , 1979, The Lancet.

[3]  S. Ekins,et al.  Further characterization of the expression in liver and catalytic activity of CYP2B6. , 1998, The Journal of pharmacology and experimental therapeutics.

[4]  T. Ishizaki,et al.  Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study , 1999, Clinical pharmacology and therapeutics.

[5]  K. Mizutani,et al.  Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro. , 1999, British journal of anaesthesia.

[6]  Jouni Ahonen,et al.  The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam , 1996, Anesthesia and analgesia.

[7]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[8]  K. Mizutani,et al.  I.v. fentanyl decreases the clearance of midazolam. , 1997, British journal of anaesthesia.

[9]  W. Trager,et al.  Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.

[10]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[11]  T. Kronbach,et al.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.

[12]  J P Perdrix,et al.  Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. , 1998, British journal of anaesthesia.

[13]  C. Wandel,et al.  Midazolam is metabolized by at least three different cytochrome P450 enzymes. , 1994, British journal of anaesthesia.

[14]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.

[15]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[16]  F. Gonzalez,et al.  Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450 , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  G. F. Weber,et al.  Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. , 1993, Cancer research.

[18]  J. Stevens,et al.  Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[19]  M. Murray,et al.  Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. , 1989, Molecular pharmacology.

[20]  I. Stupans,et al.  Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6 beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro. , 1994, The Journal of pharmacology and experimental therapeutics.

[21]  I. Roots,et al.  Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. , 1987, The Journal of pharmacology and experimental therapeutics.

[22]  P. Neuvonen,et al.  Effect of Diltiazem on Midazolam and Alfentanil Disposition in Patients Undergoing Coronary Artery Bypass Grafting , 1996, Anesthesiology.